Leidi.com Lei Jianping July 10
Gansu Haotian Technology Co., Ltd. (abbreviation: "Haotian Technology") recently submitted a prospectus and is preparing to be listed on the Science and Technology Innovation Board. Haotian Technology plans to raise 823 million yuan.
Among them, 533 million yuan was used for the construction project of high active raw material drug production base, 110 million yuan was used for the construction project of characteristic raw material drug CDMO platform, and 180 million yuan was used for the supplementary working capital project.
Annual revenue 288 million
Oriented to innovative pharmaceutical companies, Haotian Technology provides CDMO and CRO services in the design, synthesis and functional application of high-end pharmaceutical raw materials and their key intermediates, adjuvants and other functional molecules.
According to the prospectus, the revenue of Haotian Technology in 2020, 2021, and 2022 will be 140 million yuan, 244 million yuan, and 288 million yuan respectively; the net profit will be 9.7 million yuan, 30.3275 million yuan, and 47.41 million yuan; They are 7.9777 million yuan, 28.1839 million yuan and 44.8 million yuan respectively.
Xue Jijun controls 39% of the shares
Xue Jijun directly holds 10,674,541 shares of Haotian Technology, accounting for 23.7212% of the total share capital of Haotian Technology; Nuo Rui and Hao Nuo Ruize control 6,836,498 shares of Hao Tian Technology, accounting for 15.1922% of the total share capital of Hao Tian Technology.
Xue Jijun serves as the chairman and general manager of Haotian Technology, as well as the legal representative of Haotian Technology, and has a major influence on the decision-making of Haotian Technology's shareholders' meeting and the board of directors.
To sum up, Xue Jijun controls a total of 38.9134% of the shares of Haotian Technology, and serves as the chairman and general manager of Haotian Technology. He is the controlling shareholder and actual controller of Haotian Technology.
Xue Jijun, born in 1976, has a doctoral degree. From October 2004 to February 2006, he served as a research assistant at the University of Hong Kong; from June 2006 to the present, he served as a lecturer and associate professor at Lanzhou University; Executive Dean of Lanzhou University Baiyin Industrial Technology Research Institute; since April 2009, he has served as the chairman and core technical staff, and since September 2021, he has served as the general manager of the company.
Before the IPO, Haoyuan Medicine held 9.72%, Haonuo Fuze held 9.56%, Haonuo Jiacheng held 9.1%, Baiyin Kejian held 7.78%, Lanzhou Biotech held 5.9%, Kaijia Investment The shareholding is 5.33%, Hongkun Desheng holds 3.81%, and Shanghai Hao Nuorui holds 3.27%.
Shanghai Hao Ze Nuo holds 2.93%, Hao Nuo Ruize holds 2.83%, Gong Zeren holds 2.39%, Gao Xiande holds 1.94%, Jifeng No. 3 holds 1.9%, and Li Ying holds 1.8%, Zhao Jianguang holds 1.75%, Zhenjin Investment holds 1.35%, Zhongliu Lianchuang holds 1.11%, Yangzhou Yaorong Circle, Shenzhen Contra, and Gongshang Huifu hold 0.95% respectively. Jianyuan Chaohong, Fuquan Phase I, and Jianyuan Boyi hold 0.32% of the shares.
After the IPO, Xue Jijun directly held 17.79% of the shares, Haoyuan Pharmaceuticals held 7.29%, Haonuo Fuze held 7.17%, Haonuo Jiacheng held 6.82%, Baiyin Kejian held 5.83%, Lanzhou Biotech held The shareholding is 4.42%, Kaijia Investment holds 4%, Hongkun Desheng holds 2.86%, Shanghai Hao Nuo Rui holds 2.45%, Shanghai Hao Ze Nuo holds 2.2%, and Hao Nuo Ruize holds 2.12%;
Gong Zeren holds 1.79%, Gao Xiande holds 1.46%, Jifeng No. 3 holds 1.43%, Li Ying holds 1.35%, Zhao Jianguang holds 1.31%, and Zhenjin Investment holds 1.01%. Liulian Chuang holds 0.83% of the shares, Yangzhou Yaorong Circle, Shenzhen Contra, and Gongshang Huifu each hold 0.71% of the shares, and Jianyuan Chaohong, Fuquan Phase I, and Jianyuan Boyi hold 0.24% of the shares.
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
